NCT04883242View on ClinicalTrials.gov

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2031

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO or IV

BIOLOGICAL

Isatuximab

Given IV

DRUG

Pomalidomide

Given PO

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Skeletal Survey X-Ray

Undergo skeletal x-ray

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Positron Emission Tomography

Undergo PET-CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Washington

OTHER